Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis
Abstract
Leonard Krilov and colleagues present their study “Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35
Weeks Gestation for Health Plans in the United States” in the January 2010 issue of Value in Health [1]. We take this opportunity to express our concerns about the study’s methodology and conclusions.
Weeks Gestation for Health Plans in the United States” in the January 2010 issue of Value in Health [1]. We take this opportunity to express our concerns about the study’s methodology and conclusions.
Authors
Christian Hampp Teresa L. Kauf Almut G. Winterstein